A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection

Administered By

Awarded By

Contributors

Start/End

  • April 12, 2021 - April 11, 2024